Tag
Low-dose rivaroxaban failed to reduce cardiovascular events but increased major bleeding in advanced CKD patients at high cardiovascular risk, underscoring the need for cautious anticoagulant use.
This article reviews the incidence and predictors of recurrent VTE following anticoagulation for isolated distal deep vein thrombosis, highlighting key risk factors and implications for treatment duration and patient management.
Routine oral rivaroxaban prophylaxis in ACTH-dependent Cushing syndrome was associated with no new VTE events after implementation and no bleeding complications, suggesting it is a safe and effective preventive strategy.
A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populat
The APERITIF trial explored adding low-dose rivaroxaban to standard dual antiplatelet therapy to prevent heart clots after an anterior heart attack. While the addition did not significantly reduce thrombus formation, it did increase minor b
A VOYAGER-PAD sub-analysis reveals that patients with prior limb revascularization are at significantly higher risk for adverse events but derive a greater relative benefit from low-dose rivaroxaban plus aspirin.
The APERITIF randomized clinical trial found that adding low-dose rivaroxaban to dual antiplatelet therapy (DAPT) did not significantly reduce the incidence of left ventricular thrombus at one month in anterior STEMI patients, while signifi
The multicenter BRAIN-AF trial found that rivaroxaban did not prevent cognitive decline or stroke in patients with atrial fibrillation and low CHA2DS2-VASc scores. Despite significant cognitive deterioration observed across both groups, the
In patients who underwent successful catheter ablation for atrial fibrillation at least one year earlier, rivaroxaban did not significantly reduce the composite of clinical or covert embolic stroke compared with aspirin over 3 years, while
The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding
The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding
This post hoc AFIRE trial analysis shows rivaroxaban monotherapy reduces major cardiovascular events and major bleeding across age groups in AF with stable CAD, with notable age-related efficacy and safety trends warranting further research
The NEW-AF trial compared rivaroxaban and warfarin in new-onset atrial fibrillation after cardiac surgery, finding no difference in length of hospital stay but greater patient convenience and similar safety with rivaroxaban.
An 18-month course of rivaroxaban significantly lowers recurrent venous thromboembolism compared to 6 months in cancer patients with low-risk pulmonary embolism without a substantial increase in major bleeding risk.
The ARIVA trial found no superior benefit of adding aspirin to rivaroxaban over rivaroxaban alone in preventing venous stent thrombosis within 6 months post-intervention in post-thrombotic syndrome patients, with both regimens showing high
The AZALEA-TIMI 71 trial shows abelacimab, a novel factor XI inhibitor, reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients on antiplatelet therapy, suggesting a safer anticoagulation alternative.
